PhRMA Delegation Meets China Pharmaceutical Organizations
This article was originally published in PharmAsia News
Representatives from the Pharmaceutical Research and Manufacturers of America recently attended an international summit in Beijing on new drug R&D policies and practices hosted by the Healthcare Policy Research Center of Chinese Pharmaceutical Association. The center expressed the wish of strengthening both countries' cooperation in drug production to the American delegation, which included top-level executives from key multinational companies such as Bristol-Myers Squibb, Lilly, Genzyme, GlaxoSmithKline, MSD Pharma (Merck's India arm), Novartis, Pfizer, Schering-Plough and Wyeth. The U.S. group held exchanges with officials from China's State FDA and the Ministry of Health on supervisory issues about developing new drugs globally and conducting multicenter clinical trials. Members from China Health & Medical Development Foundation, Chinese Pharmaceutical Association and China Pharmaceutical Industry Association also joined in discussions to boost collaboration. (Click here for more - Chinese Language)
You may also be interested in...
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.